BioCentury
BioCentury
YouTubeLinkedInXRSS
ARTICLE | Product Development

A guide to COVID-19 preclinical vaccine modalities

Danielle Kopke, Staff Writer
May 16, 2020 2:36 AM UTC
Updated on May 16, 2020 at 3:02 AM UTC

As the number of vaccines in development for COVID-19 climbs past 110, more modalities are starting to be represented in the clinic.

As of last week, the COVID-19 vaccine modalities in the clinic were inactivated viruses, vector-based vaccines and nucleic acids (see “A Guide to COVID-19 Vaccine Modalities in the Clinic“)...

BCIQ Target Profiles

MERS-CoV S protein

SARS-CoV-2 envelope protein (SARS-CoV-2 E)

SARS-CoV-2 membrane protein (SARS-CoV-2 M)

SARS-CoV-2 nucleocapsid protein (SARS-CoV-2 N)

SARS-CoV-2 spike protein (SARS-CoV-2 S)

Severe acute respiratory syndrome coronavirus (SARS-CoV) S protein (SARS S)

BCIQ Target Profiles

MERS-CoV S protein

SARS-CoV-2 envelope protein (SARS-CoV-2 E)

SARS-CoV-2 membrane protein (SARS-CoV-2 M)

SARS-CoV-2 nucleocapsid protein (SARS-CoV-2 N)

SARS-CoV-2 spike protein (SARS-CoV-2 S)

Severe acute respiratory syndrome coronavirus (SARS-CoV) S protein (SARS S)

About BioCentury

Privacy & Legal

Contact

About BioCentury

Company Overview
Management
Editorial & Research
Scientific Advisory Board

Privacy & Legal

User Agreement
Terms of Use
Privacy Policy
Use of Images & Market Data
Reprints & Permissions

Contact

Contact Us
Advertising & Sponsorship
Customer Resource Center
Career Opportunities
Forgot Password
YouTubeLinkedInXRSS
BioCentury
© 2026 BioCentury Inc. All Rights Reserved.
Copyright © 2026 BioCentury Inc. All Rights Reserved.
YouTubeLinkedInXRSS